Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Eric Bruce
Eric Bruce Biehr, Milwaukee, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20120076277 | ASYNCHRONOUS MOTOR WITH FEATURES CREATING MAGNETIC FIELD DISTURBANCE - A component for introducing disturbances into the magnetic field of an asynchronous motor by altering a reluctance of the motor is disclosed. An asynchronous motor is provided that includes a stator having a plurality of windings that is configured to generate a rotating magnetic field when a current is provided to the plurality of windings. The asynchronous motor also includes a rotor positioned within the stator configured to rotate relative thereto responsive to the rotating magnetic field and a component separate from the stator and the rotor that is positioned within the rotating magnetic field, with the component being configured to alter a magnetic reluctance of the rotor so as create a disturbance in the rotating magnetic field. | 03-29-2012 |
Eric Bruce Haura, Tampa, FL US
| Patent application number | Description | Published |
|---|---|---|
| 20100004257 | Identification of Biomarkers Predictive of Dasatinib Effects in Cancer Cells - A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents. | 01-07-2010 |
Eric Bruce Koefoot, Oakton, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20090106236 | Method for scoring products, services, institutions, and other items - The present invention relates to a method of scoring an item, including reviewing a first editorial evaluation of the item; assigning a first editorial evaluation score to the item based on the first editorial evaluation; reviewing a second editorial evaluation of the item; assigning a second editorial evaluation score to the item based on the second editorial evaluation; and calculating a score for the item based on the first editorial evaluation score and the second editorial evaluation score. The item score may also be calculated based upon component scores for the item or quantitative ratings. | 04-23-2009 |
Eric Bruce Springman, East Norriton, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090192307 | INHIBITORS OF PROTEIN KINASES - The present invention is directed to a compound having the formula | 07-30-2009 |